[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-failure-acute-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-failure-acute-chronic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100637453","impact-of-trans-catheter-aortic-valve-implantation-on-renal-function-100637453",false,"NCT07626710","Impact of Trans-catheter Aortic Valve Implantation on Renal Function","Impact of Trans-catheter Aortic Valve Implantation on Kidney Response to Contrast Dye Administration: an Observational Registry","TAVIKOD","Inclusion Criteria:\n\n* Age \\>18 years with a life expectancy \\>1 year;\n* Patient candidate for percutaneous aortic valve implantation after formal indication of our \"Heart Team\".\n* Patient performed at least one contrast-based exam other than the TAVI procedure in the previous two months.\n* Patients had adequate renal function assessment after each contrast medium administration (TAVI procedure included) with at least three post-procedural measurements in the following 5 days.\n* Patients were informed of the possibility to be the object of anonymized data collection for study protocols approved by the internal Ethical Committee and had provided written informed consent to the procedure (for patients before 2018) or had provided written informed consent to the research purposes of IRCCS (for patients from 2018 to date).\n\nExclusion Criteria:\n\n* Female with childbearing potential or lactating;\n* Acute or chronic end-stage renal dysfunction defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2);\n* Candidate for dialysis treatment;\n* Co-morbidities that could interfere with the completion of study procedures, or life expectancy of less than 1 year;\n* Absent or incomplete renal function assessment after each contrast-based procedure;\n* Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study;","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","5 Years","OBSERVATIONAL","Both contrast-induced acute kidney injury (AKI) and pre-existing chronic kidney disease are associated with an increased mortality risk in patients requiring aortic valve replacement. Nonetheless, the direct haemodynamic impact of the aortic barrage (i.e. pre-renal mechanism) on renal function compromising and its reversibility in patients undergoing trans-catheter aortic valve implantation (TAVI) is unknown.\n\nThis registry aims to evaluate the effect of severe aortic stenosis removal on the risk of contrast-induced acute renal injury (CI-AKI) during TAVI procedures and on renal function evolution",[26,27,28],"Aortic Valve Stenosis","Chronic Kidney Diseases","Renal Failure Acute Chronic",[30,31,32,33],"Trans-catheter aortic valve implantation","Contrast-induced acute renal injury","Kidney failure","Observational registry","RECRUITING","2026-05-31",{"date":37,"type":38},"2026-06-04","ACTUAL",{"date":40,"type":38},"2024-08-30",{"date":42,"type":21},"2033-08-30",{"name":44,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100306978","bispectral-electroencephalography-eeg-in-first-time-hemodialysis-100306978","NCT03276273","Bispectral-Electroencephalography (EEG) in First Time Hemodialysis","The Utility of Using the Bispectral Index (BIS) for Detecting Dialysis Disequilibrium Syndrome (DDS)","BIS7","Inclusion Criteria:\n\n* First Time renal Dialysis\n\nExclusion Criteria:\n\n* subjects' consumption of sedatives\u002Fhypnotics psychotropic drugs, or concomitant neurological disorders affecting mental state such as hepatic encephalopathy, stroke, stupor or dementia and renal transplant patients.","90 Years",{"count":57,"type":21},20,"The severity of minimal dialysis disequilibrium syndrome (DDS) is currently detected and graded clinically using clinical criteria. Bispectral Index (BIS), an electroencephalographic (EEG) derived parameter is widely used in anesthesia and Critical Care setting to detect effects of anesthetic\u002Fhypnotic drugs. The aim of our study was to assess the discriminative power of BIS monitoring to accurately detect DDS.",[28],"2026-04-22",{"date":62,"type":38},"2026-04-28",{"date":64,"type":38},"2017-05-01",{"date":66,"type":21},"2027-12-01",{"name":68,"class":45},"Suez Canal University",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100593320","efficacy-and-tolerability-of-the-apd-treatment-in-paed-patients-100593320","NCT07004907","Efficacy and Tolerability of the APD Treatment in PAED Patients","Efficacy and Tolerability of the APD Treatment of Toddlers and Newborns With the Silencia PD Cycler","SilenciaPAED","Inclusion Criteria:\n\n* Informed consent signed and dated by legal representative and investigator\u002Fauthorized physician\n* The minors have received the information referred to in Article 63(2) MDR in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children\n* The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator\n* patients with renal failure treated or planned to be treated with APD\n* Body weight ≤ 20 kg\n* Ability to understand the nature and requirements of the study\n\nExclusion Criteria:\n\n* Any conditions which could interfere with the patient's ability to comply with the study\n* Patient or legal representative is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations\n* Participation in an interventional clinical study during the preceding 30 days\n* Previous participation in the same study\n* Life expectancy \\\u003C 3 months\n* Patients who suffer from peritonitis\u002Fexit site infection during the last 4 weeks","0 Months",{"count":80,"type":21},13,"INTERVENTIONAL",[83],"NA","The Silencia PD (peritoneal dialysis) cycler offers a pediatric (PAED) mode with advanced features such as Time and Volume Optimization (TAVO), supporting precise and individualized treatment. This study evaluates the efficacy and tolerability of Automated Peritoneal Dialysis (APD) using the Silencia PD cycler in patients weighing ≤ 20 kg and able to tolerate a minimum inflow volume of 100 mL. The primary objective is to determine whether patients achieve a total weekly Kt\u002FVurea ≥ 1.8.",[28],[87,88,89,90,91],"Automated peritoneal dialysis","paedriatic patients","Kt\u002FV","ultrafiltration","Chronic Kidney Disease","NOT_YET_RECRUITING","2025-06-02",{"date":95,"type":38},"2025-06-04",{"date":97,"type":21},"2026-01",{"date":99,"type":21},"2026-11",{"name":101,"class":102},"Fresenius Medical Care Deutschland GmbH","INDUSTRY"]